# EDGAR Filing Document

**Accession Number:** 0001708688
**File Stem:** 0001213900-26-029793
**Filing Date:** 2026-3
**Character Count:** 10729
**Document Hash:** 147abc6aab9f09750491599b00e6b540
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-029793.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001213900-26-029793

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** OCarroll Derval
- **CENTRAL INDEX KEY:** 0002117350

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38283
- **FILM NUMBER:** 26765524

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O INFLARX N.V.
- **STREET 2:** WINZERLAER STREET 2
- **CITY:** JENA
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 07745
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InflaRx N.V.
- **CENTRAL INDEX KEY:** 0001708688
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** WINZERLAER STR. 2
- **CITY:** JENA
- **STATE:** 2M
- **ZIP:** 07745
- **BUSINESS PHONE:** 49 3641 508180

**MAIL ADDRESS:**
- **STREET 1:** WINZERLAER STR. 2
- **CITY:** JENA
- **STATE:** 2M
- **ZIP:** 07745

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Fireman B.V.
- **DATE OF NAME CHANGE:** 20170606

## Exhibit 24.1

**Exhibit 24.1**

**POWER OF ATTORNEY**

**FOR SECTION 13 & 16 REPORTING OBLIGATIONS**

KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Christian Schmid, Thomas Taapken, and Niels Riedemann of lnflaRx N. V. and Sophia Hudson and Leia Andrew of Kirkland & Ellis LLP, each signing singly, as the undersigned's true and lawful attorney-in-fact and agent, with full power and authority, including substitution and revocation, as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) prepare, execute, acknowledge, deliver and file any Schedule 13D or Schedule
13G, and any amendments, supplements or exhibits thereto (including any joint filing agreements) required to be filed by the undersigned
under Section 13 of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder (the "Exchange Act"),
and any Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of InflaRx N.V., a Netherlands public limited
liability company, or any successor thereto (the "Company"), with the U.S. Securities and Exchange Commission, any national
securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Exchange Act and the rules and regulations
promulgated thereunder, as amended from time to time under the Exchange Act as well as notices on Form 144 and amendments thereto, filed
pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended (the "Securities Act");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) seek or obtain, as the undersigned's representative and on the undersigned's
behalf, information of transactions in the Company's securities from any third-party, including brokers, employee benefit plan administrators
and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and
ratifies any such release of information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) perform any and all other acts which in the discretion of such attorney-in-fact
is necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) this Power of Attorney authorizes, but does not require, such attorney-in-fact
to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) any documents prepared, executed, acknowledged and/or delivered by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information
and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) neither the Company nor such attorney-in-fact assumes (i) any liability
for the undersigned's responsibility to comply with the requirements of the Exchange Act, or the Securities Act, as applicable (ii)
any liability of the undersigned for any failure to comply with such requirements, (iii) any obligation or liability of the undersigned
for profit disgorgement under Section 16(b) of the Exchange Act, or (iv) any liability for failure to quality for the safe harbor Rule
144; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under the Exchange Act, or Securities Act, as applicable, including without limitation
the reporting requirements under Section 13 and/or Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the 18<sup>th</sup> day of March, 2026.

---

| | |
|:---|:---|
| By: | /s/ Derval O'Carroll |
| Name: | Derval O'Carroll |
| Title: | Senior Vice President, Global Head of Regulatory Affairs and Compliance |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>OCarroll Derval<br><sub>(Last) (First) (Middle)</sub><br>C/O INFLARX N.V.<br>WINZERLAER STREET 2<br><sub>(Street)</sub><br>JENA, GERMANY 07745<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>InflaRx N.V. [ IFRX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_See Remarks_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2032-11-21 | Ordinary Shares | 20000 | $2.44 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2033-01-24 | Ordinary Shares | 25000 | $2.37 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2034-01-05 | Ordinary Shares | 45000 | $1.79 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2035-01-03 | Ordinary Shares | 70000 | $2.41 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2036-01-06 | Ordinary Shares | 70000 | $1.17 | D |  |
| Performance Stock Option (Right to Buy) | <sup>(6)</sup> | 2036-01-06 | Ordinary Shares | 21000 | $1.17 | D |  |

---

### Footnotes:

(1) This option was granted on November 21, 2022 and is fully vested and exercisable as of the date hereof.

(2) This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.

(3) This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

(4) This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

(5) This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 17,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

(6) This option shall vest depending upon achievement of the following performance criteria: (i) 50% shall vest if a certain financing event takes place before the fourth quarter of 2026 and (ii) 50% shall vest if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.

**Remarks:**
Senior Vice President, Global Head of Regulatory Affairs and Compliance
 Exhibit List - Exhibit 24.1 Power of Attorney

**Signature:** /s/ Christian Schmid, Attorney-in-Fact  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**